Literature DB >> 8465127

Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.

W M Linehan1, M M Walther, R B Alexander, S A Rosenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8465127

Source DB:  PubMed          Journal:  Semin Urol        ISSN： 0730-9147


× No keyword cloud information.
  9 in total

1.  Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.

Authors:  Yosuke Yasuda; Kazutaka Saito; Takeshi Yuasa; Sho Uehara; Naoko Kawamura; Minato Yokoyama; Junichiro Ishioka; Yoh Matsuoka; Shinya Yamamoto; Tetsuo Okuno; Junji Yonese; Kazunori Kihara; Yasuhisa Fujii
Journal:  Int J Clin Oncol       Date:  2017-07-21       Impact factor: 3.402

2.  IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.

Authors:  Kevin C Conlon; E Lake Potter; Stefania Pittaluga; Chyi-Chia Richard Lee; Milos D Miljkovic; Thomas A Fleisher; Sigrid Dubois; Bonita R Bryant; Michael Petrus; Liyanage P Perera; Jennifer Hsu; William D Figg; Cody J Peer; Joanna H Shih; Jason L Yovandich; Stephen P Creekmore; Mario Roederer; Thomas A Waldmann
Journal:  Clin Cancer Res       Date:  2019-05-29       Impact factor: 12.531

3.  Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis.

Authors:  Shinsuke Hamada; Keiichi Ito; Kenji Kuroda; Akinori Sato; Junichi Asakuma; Akio Horiguchi; Kenji Seguchi; Tomohiko Asano
Journal:  Mol Clin Oncol       Date:  2014-09-29

4.  Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy.

Authors:  Michael J Gough; N Killeen; Andrew D Weinberg
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

5.  Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.

Authors:  Daiki Ueno; Masahiro Yao; Ukihide Tateishi; Ryogo Minamimoto; Kazuhide Makiyama; Narihiko Hayashi; Futoshi Sano; Takayuki Murakami; Takeshi Kishida; Takeshi Miura; Kazuki Kobayashi; Sumio Noguchi; Ichiro Ikeda; Yoshiharu Ohgo; Tomio Inoue; Yoshinobu Kubota; Noboru Nakaigawa
Journal:  BMC Cancer       Date:  2012-05-02       Impact factor: 4.430

6.  Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.

Authors:  Kazuhiro Namura; Ryogo Minamimoto; Masahiro Yao; Kazuhide Makiyama; Takayuki Murakami; Futoshi Sano; Narihiko Hayashi; Ukihide Tateishi; Hanako Ishigaki; Takeshi Kishida; Takeshi Miura; Kazuki Kobayashi; Sumio Noguchi; Tomio Inoue; Yoshinobu Kubota; Noboru Nakaigawa
Journal:  BMC Cancer       Date:  2010-12-03       Impact factor: 4.430

7.  Current status of targeted therapy for advanced renal cell carcinoma.

Authors:  In-Chang Cho; Jinsoo Chung
Journal:  Korean J Urol       Date:  2012-04-18

8.  FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma.

Authors:  Noboru Nakaigawa; Keiichi Kondo; Ukihide Tateishi; Ryogo Minamimoto; Tomohiro Kaneta; Kazuhiro Namura; Daiki Ueno; Kazuki Kobayashi; Takeshi Kishida; Ichiro Ikeda; Hisashi Hasumi; Kazuhide Makiyama; Yoshinobu Kubota; Tomio Inoue; Masahiro Yao
Journal:  BMC Cancer       Date:  2016-02-08       Impact factor: 4.430

9.  The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ.

Authors:  Manabu Kakizoe; Masahiro Yao; Ukihide Tateishi; Ryogo Minamimoto; Daiki Ueno; Kazuhiro Namura; Kazuhide Makiyama; Narihiko Hayashi; Futoshi Sano; Takeshi Kishida; Kazuki Kobayashi; Sumio Noguchi; Ichiro Ikeda; Yoshiharu Ohgo; Masataka Taguri; Satoshi Morita; Tomio Inoue; Yoshinobu Kubota; Noboru Nakaigawa
Journal:  BMC Cancer       Date:  2014-06-02       Impact factor: 4.430
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.